LCP4 treatment reduces the percentage of JAK2V617F+ and homozygous JAK2V617F+ HPCs generated
| Patient # . | Treatment . | CFU-GM . | |
|---|---|---|---|
| . | . | % JAK2V617F+ . | % Homozygous JAK2V617F+ . |
| SP18 | Cytokines alone | 35 (17/48)* | 13 (6/48) |
| Cytokines + LCP4 100 nM | 26 (9/35) | 11 (4/35) | |
| SP19 | Cytokines alone | 92 (33/36) | 81 (29/36) |
| Cytokines + LCP4 100 nM | 72 (13/18) | 61 (11/18) | |
| PB158 | Cytokines alone | 100 (36/36) | 86 (31/36) |
| Cytokines + LCP4 100 nM | 91 (30/33) | 85 (28/33) | |
| PB177 | Cytokines alone | 97 (34/35) | 57 (20/35) |
| Cytokines + LCP4 100 nM | 65 (17/26) | 23 (6/26) | |
| PB195 | Cytokines alone | 85 (29/34) | 0 (0/34) |
| Cytokines + LCP4 100 nM | 60 (18/30) | 0 (0/30) | |
| Patient # . | Treatment . | CFU-GM . | |
|---|---|---|---|
| . | . | % JAK2V617F+ . | % Homozygous JAK2V617F+ . |
| SP18 | Cytokines alone | 35 (17/48)* | 13 (6/48) |
| Cytokines + LCP4 100 nM | 26 (9/35) | 11 (4/35) | |
| SP19 | Cytokines alone | 92 (33/36) | 81 (29/36) |
| Cytokines + LCP4 100 nM | 72 (13/18) | 61 (11/18) | |
| PB158 | Cytokines alone | 100 (36/36) | 86 (31/36) |
| Cytokines + LCP4 100 nM | 91 (30/33) | 85 (28/33) | |
| PB177 | Cytokines alone | 97 (34/35) | 57 (20/35) |
| Cytokines + LCP4 100 nM | 65 (17/26) | 23 (6/26) | |
| PB195 | Cytokines alone | 85 (29/34) | 0 (0/34) |
| Cytokines + LCP4 100 nM | 60 (18/30) | 0 (0/30) | |
The numbers in parentheses denote the actual number of total JAK2V617F+ or homozygous JAK2V617F+ CFU-GM / the total numbers of CFU-GM plucked and genotyped.